HCA
ADAP

Harbor Capital Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Harbor Capital Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-188,070
Closed -$297K – 726
2024
Q1 		$297K Buy
188,070
+40,338
+27% +$48.7K 0.04% 523
2023
Q4 		$117K Buy
147,732
+13,317
+10% +$7.51K 0.02% 407
2023
Q3 		$105K Buy
134,415
+21,899
+19% +$18.4K 0.02% 414
2023
Q2 		$104K Buy
+112,516
New +$134K 0.02% 428

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Harbor Capital Advisors's ADAP Position: Q2 2024 in Review

Harbor Capital Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q2 2024, closing a stake of 188,070 shares — an estimated $297K sold.

Harbor Capital Advisors first reported a position in ADAP in Q2 2023 and held it in 4 quarters. The position peaked at $297K in Q1 2024. 76 funds tracked by Wall St. Rank hold ADAP as of Q2 2024.

  • Harbor Capital Advisors reported no remaining Adaptimmune Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Harbor Capital Advisors sold 188,070 Adaptimmune Therapeutics shares in Q2 2024, an estimated $297K.
  • Harbor Capital Advisors first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 4 quarters.
  • Harbor Capital Advisors's Adaptimmune Therapeutics position peaked at $297K in Q1 2024.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2024.

Based on Harbor Capital Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.